Combination of All-Trans Retinoic Acid Resumes the Sustained Response of TPO-RA in ITP
November 2024
in “
Blood
”
TLDR Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.
The study investigated the effectiveness of combining all-trans retinoic acid (ATRA) with thrombopoietin receptor agonists (TPO-RA) to stabilize platelet counts in idiopathic thrombocytopenic purpura (ITP) patients. Conducted at Nanfang Hospital, the study included 15 patients after excluding 2 due to severe headaches. The results showed that ATRA effectively resumed platelet response in 86.67% of cases, with a median treatment duration of 94 days. Side effects were generally tolerable, with 13.33% experiencing dry and cracked lips, 6.67% experiencing headaches, 13.33% experiencing hair loss, and 6.67% experiencing rashes. The study concluded that short-term ATRA treatment is both effective and safe for managing platelet fluctuations in ITP patients on TPO-RA therapy.